You may find more results for this query on our sister sites: 360Dx and Precision Oncology News.
The deals are with institutional investors and more than 1 million American Depositary Shares will be offered at A$1.75 per ADS.
The firm plans to use the cash to support commercial expansion of its NIPT to all US states and fund R&D for future diagnostic tests, including liquid biopsies.
The Cambridge, UK-based gene synthesis firm plans to use the funds to accelerate development of its silicon platform and introduce a desktop device.
La Jolla, California-based DermTech has agreed to sell common and preferred stock to a number of undisclosed institutional investors.
The financing follows InformedDNA's signing of definitive agreements to receive growth capital investments with a number of investment groups.
The company is developing an RNA sequencing kit based on a technology that enables barcoding in a test tube format to prepare samples for single-cell profiling.
The company is developing a platform that is designed to provide an overview of an individual's health based on sequenced genetic data and other metrics.
The Series B round, which includes new and existing investors, follows the Belgian firm's completion of a €7.7 million private placement in 2016.
The firm, cofounded by several Harvard University researchers, is commercializing a single-cell spatial transcriptomics technology called MERFISH.
The University of Utah spinout said it will use the funding to enhance and expand its NGS-based Explify microbe identification platform and support its lab.
A German shepherd called Nala has had her genome sequenced.
A coronavirus serology test garners Emergency Use Authorization from the US Food and Drug Administration, but the Los Angeles Times asks: how will tests like that be used?
Certain gene variants in conjunction with a healthy lifestyle may keep brains young, according to New Scientist.
In Science this week: increased CD8 T cell density and increased IFN-gamma response may indicate metastatic prostate cancer patients who will respond to immune checkpoint blockade therapy.